Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nachbagauer

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Biorxiv : the Preprint Server for Biology|December 23, 2024
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoproteinSameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, et al.
Science Immunology|October 10, 2025
Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunizationSameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, et al.
Biorxiv : the Preprint Server for Biology|September 29, 2022
SARS-CoV-2 Omicron boosting induces de novo B cell response in humansWafaa B Alsoussi, Sameer K Malladi, Julian Q Zhou, et al.
Nature|December 23, 2021
Broadly neutralizing antibodies target a haemagglutinin anchor epitopeJenna J Guthmiller, Julianna Han, Henry A Utset, et al.
Nature|April 3, 2023
SARS-CoV-2 Omicron boosting induces de novo B cell response in humansWafaa B Alsoussi, Sameer Kumar Malladi, Julian Q Zhou, et al.
Immunity|August 14, 2020
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in MiceDorottya Laczkó, Michael J Hogan, Sushila A Toulmin, et al.
Immunity|March 25, 2025
Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutininsJenna J Guthmiller, Linda Yu-Ling Lan, Lei Li, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Biorxiv : the Preprint Server for Biology|December 23, 2024
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoproteinSameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, et al.
Science Immunology|October 10, 2025
Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunizationSameer Kumar Malladi, Deepika Jaiswal, Baoling Ying, et al.
Biorxiv : the Preprint Server for Biology|September 29, 2022
SARS-CoV-2 Omicron boosting induces de novo B cell response in humansWafaa B Alsoussi, Sameer K Malladi, Julian Q Zhou, et al.
Nature|December 23, 2021
Broadly neutralizing antibodies target a haemagglutinin anchor epitopeJenna J Guthmiller, Julianna Han, Henry A Utset, et al.
Nature|April 3, 2023
SARS-CoV-2 Omicron boosting induces de novo B cell response in humansWafaa B Alsoussi, Sameer Kumar Malladi, Julian Q Zhou, et al.
Immunity|August 14, 2020
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in MiceDorottya Laczkó, Michael J Hogan, Sushila A Toulmin, et al.
Immunity|March 25, 2025
Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutininsJenna J Guthmiller, Linda Yu-Ling Lan, Lei Li, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.
Pageof 11